There is an urgent need for a pharmacological agent that can specifically and safely correct the shared metabolic pathology, ideally by acting at both central (e.g., controlling appetite and cravings) and peripheral (e.g., improving insulin sensitivity, reducing hepatic fat and inflammation) levels to support and enhance existing behavioral strategies, thereby lowering the risk of advanced liver disease development across metabolic and alcoholic etiologies
Protein intake is key, along with making sure youre getting the right vitamins and nutrients, Dana says
It's important to note that these are sold as research chemicals and are labelled not for human use
A 2017 meta-analysis puts it like this: Composite probiotics containing B
PEGylating or fusing peptide with albumin/Fc domain are also feasible and even the DPP-4 would be resisted by steric hindrance if the latter method is taken
Ros team runs that pipeline for you